Viracta Therapeutics, Inc. (VIRX) Reports In-Line Q3 EPS

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance